CryoBalloon Ablation for Treatment of Duodenal Adenomas
| 対象疾患 | Duodenal Adenomas, Familial Adenomatous Polyposis |
|---|---|
| 相 | 該当なし |
| スポンサー | Johns Hopkins University |
| ステータス | 完了 |
| 参加者数 | 33 名 |
| 介入（薬剤） | CryoBalloon ablation |
| 開始日 | 2019年5月13日 |
| 完了日 | 2025年6月1日 |
| 結果公開日 | 2026年8月4日 |
概要
This multicenter prospective non-randomized interventional study (clinical trial) that will assess the safety and efficacy of cryoballoon ablation treatment using the C2 Cryoballoon device (Pentax Medical Corporation) as an alternative primary treatment modality for sporadic and familial nonampullary nonpolypoid (flat) duodenal adenomas.
Safety of CryoBalloon Ablation in Treating Non-ampullary Non-polypoid Duodenal Adenomas (DAs) as Assessed by Participants With Adverse Events
| Individuals With Duodenal Adenomas | 12 Participants |
|---|
Participants With Complete Eradication of DA
| Individuals With Duodenal Adenomas | 23 Participants |
|---|
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refract — Jennerex Biotherapeutics
- Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III — National Cancer Institute (NCI)
- Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps — National Cancer Institute (NCI)
- Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal — National Cancer Institute (NCI)
- Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating — National Cancer Institute (NCI)
- Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 — National Cancer Institute (NCI)